Pathologic evaluation of unknown primary cancer.

The pathologic approach to metastases of unknown primary cancer (UPC) is stepwise and uses the clinical context, morphology, and, where necessary, immunohistochemistry (IHC). This review covers the initial approach to a UPC biopsy; the diagnosis of malignancy and broad tumor typing into carcinoma, melanoma, lymphoma, or sarcoma; and further subtyping of carcinoma into germ cell (broadly included), squamous, neuroendocrine, and solid organ including liver and renal, and adenocarcinomas. Finally, for adenocarcinoma, the prediction of primary tumor site, including lung, pancreas, stomach, colon, ovary, prostate, and breast, is discussed. For each tumor type, the morphologic features are presented alongside established useful IHC markers, with a description of their staining patterns and common diagnostic dilemmas. Optimal tissue handling and IHC interpretation, quality assurance, and limitations also are discussed. The target readership is oncologists, but other clinicians and trainee pathologists also may find the content of use.

[1]  R. Zappatore,et al.  Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells , 1992, Cancer.

[2]  R. M. Wolf,et al.  Metastatic and histologic presentations in unknown primary cancer. , 1977, Seminars in oncology.

[3]  Van Diest,et al.  Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma , 1998, Histopathology.

[4]  Liang Cheng Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry , 2004, Cancer.

[5]  M. Saegusa,et al.  Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation. , 2008, Human pathology.

[6]  I. Kawase,et al.  Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.

[7]  Brigitte M. Ronnett,et al.  Primary and Metastatic Mucinous Adenocarcinomas in the Ovaries: Incidence in Routine Practice With a New Approach to Improve Intraoperative Diagnosis , 2003, The American journal of surgical pathology.

[8]  C. la Vecchia,et al.  Epidemiology of unknown primary tumours. , 2002, European journal of cancer.

[9]  David C. Atkins,et al.  A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. , 2006, The Journal of molecular diagnostics : JMD.

[10]  R. Alsabeh,et al.  Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. , 2008, Archives of pathology & laboratory medicine.

[11]  J. Silverman,et al.  Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. , 2004, American journal of clinical pathology.

[12]  Adam Kowalczyk,et al.  An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. , 2005, Cancer research.

[13]  I. Yang,et al.  Multi-platform, multi-site, microarray-based human tumor classification. , 2004, The American journal of pathology.

[14]  Steven Eschrich,et al.  Elucidation of a protein signature discriminating six common types of adenocarcinoma , 2007, International journal of cancer.

[15]  J. Licht,et al.  Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma , 2005, Journal of Clinical Pathology.

[16]  I. Ellis,et al.  Tumour marker immunoreactivity in adenocarcinoma. , 1988, Journal of clinical pathology.

[17]  J. K. Dunn,et al.  Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. , 1997, American journal of clinical pathology.

[18]  L. Pecciarini,et al.  Identifying the primary sites of metastatic carcinoma: the increasing role of immunohistochemistry , 2001 .

[19]  N. Pavlidis,et al.  Cancer of unknown primary site: missing primary or missing biology? , 2007, The oncologist.

[20]  A. Floore,et al.  Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary , 2008, British Journal of Cancer.

[21]  N. Pavlidis,et al.  Switching benchmarks in cancer of unknown primary: from autopsy to microarray. , 2007, European journal of cancer.

[22]  D. Silberg,et al.  Expression of intestine‐specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas , 2003, The Journal of pathology.

[23]  P. Chu,et al.  Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. , 2000, American journal of clinical pathology.

[24]  H. Hillen Unknown primary tumours , 2000, Postgraduate medical journal.

[25]  Fausto J. Rodriguez,et al.  Rosai and Ackerman’s Surgical Pathology, 9th ed. , 2004 .

[26]  K. Kerr,et al.  Thyroid transcription factor 1 in pulmonary adenocarcinoma , 2004, Journal of Clinical Pathology.

[27]  P. Chu,et al.  Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. , 2004, American journal of clinical pathology.

[28]  N. Pavlidis Cancer of unknown primary: biological and clinical characteristics. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Cochran,et al.  Immunohistochemical characteristics of melanoma , 2008, Journal of cutaneous pathology.

[30]  S. Hammar Metastatic adenocarcinoma of unknown primary origin. , 1998, Human pathology.

[31]  H. Iwata,et al.  Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers , 2007, Modern Pathology.

[32]  K. Hess,et al.  Unknown primary tumors metastatic to liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[34]  I. Downie,et al.  Positive immunostaining for thyroid transcription factor-1 in primary and metastatic colonic adenocarcinoma: a note of caution , 2006, Journal of Clinical Pathology.

[35]  S. Asa,et al.  Application of immunohistochemistry to thyroid neoplasms. , 2009, Archives of pathology & laboratory medicine.

[36]  J. Hainsworth,et al.  Treatment of patients with cancer of an unknown primary site. , 1993, The New England journal of medicine.

[37]  A. Marchevsky Application of immunohistochemistry to the diagnosis of malignant mesothelioma. , 2009, Archives of pathology & laboratory medicine.

[38]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[39]  N. Goldstein,et al.  Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. , 2001, American journal of clinical pathology.

[40]  C. Moskaluk,et al.  Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. , 2003, Human pathology.

[41]  J. Parisi,et al.  Metastatic adenocarcinoma to the brain: an immunohistochemical approach. , 1997, Human pathology.

[42]  P. V. van Diest,et al.  Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. , 1998, Human pathology.

[43]  K. Iczkowski,et al.  Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. , 2008, Human pathology.

[44]  P. Chu,et al.  Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases , 2000, Modern Pathology.

[45]  J. Silverman,et al.  Diagnostic Value of CDX-2 and TTF-1 Expressions in Separating Metastatic Neuroendocrine Neoplasms of Unknown Origin , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[46]  J. Komorowski,et al.  Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm , 2005, Clinical Cancer Research.

[47]  C. Bieberich,et al.  Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma , 2007, The American journal of surgical pathology.

[48]  C. Perou,et al.  RNA expression analysis of formalin-fixed paraffin-embedded tumors , 2007, Laboratory Investigation.

[49]  A. Bahrami,et al.  An overview of testicular germ cell tumors. , 2009, Archives of pathology & laboratory medicine.

[50]  J. Welsh,et al.  Molecular classification of human carcinomas by use of gene expression signatures. , 2001, Cancer research.

[51]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[52]  Mcnicol,et al.  Optimizing immunohistochemistry: antigen retrieval and signal amplification , 1998, Histopathology.

[53]  M. Dietel,et al.  Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites , 1996, Histopathology.

[54]  A. Gown,et al.  Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7 , 2006, Modern Pathology.

[55]  P. Chu,et al.  Keratin expression in human tissues and neoplasms , 2002, Histopathology.

[56]  J. Coebergh,et al.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. , 2002, European journal of cancer.

[57]  N. Goldstein,et al.  WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. , 2001, American journal of clinical pathology.

[58]  L. Truong,et al.  Undifferentiated tumor: true identity by immunohistochemistry. , 2009, Archives of pathology & laboratory medicine.

[59]  R. Salunga,et al.  Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. , 2009, Archives of pathology & laboratory medicine.

[60]  L. Fowler,et al.  Application of immunohistochemistry to cytology. , 2009, Archives of pathology & laboratory medicine.

[61]  S. Paydaş,et al.  Granulocytic sarcoma: 32 cases and review of the literature , 2006, Leukemia & lymphoma.

[62]  Roman Kodet,et al.  Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases , 2002, Virchows Archiv.

[63]  B. Centeno Pathology of liver metastases. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[64]  R. Lloyd,et al.  Practical Markers Used in the Diagnosis of Endocrine Tumors , 2004, Advances in anatomic pathology.

[65]  R. Lenzi,et al.  Diagnostic strategies for unknown primary cancer , 2004, Cancer.

[66]  Robert J. Marinelli,et al.  Placental S100 (S100P) and GATA3: Markers for Transitional Epithelium and Urothelial Carcinoma Discovered by Complementary DNA Microarray , 2007, The American journal of surgical pathology.

[67]  A. Haitel,et al.  Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study , 2005, Modern Pathology.

[68]  C. Haglund,et al.  A retrospective analysis of submissions, acceptance rate, open peer review operations, and prepublication bias of the multidisciplinary open access journal Head & Face Medicine , 2006, PLoS biology.

[69]  M. Rijn,et al.  Hep Par 1 Antibody Stain for the Differential Diagnosis of Hepatocellular Carcinoma: 676 Tumors Tested Using Tissue Microarrays and Conventional Tissue Sections , 2003, Modern Pathology.

[70]  S. Y. Park,et al.  Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. , 2002, Human pathology.

[71]  M. O'brien,et al.  Metastatic adenocarcinoma of an unknown primary site. A comparison of the relative contributions of morphology, minimal essential clinical data and CEA immunostaining status. , 1993, American journal of clinical pathology.

[72]  J. Bergh,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  J. Pollack,et al.  Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. , 2008, The Journal of molecular diagnostics : JMD.

[74]  K. Hess,et al.  Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  T. Wheeler,et al.  Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney). , 2008, Archives of pathology & laboratory medicine.

[76]  D. Cao,et al.  Expression of Mesothelin, Fascin, and Prostate Stem Cell Antigen in Primary Ovarian Mucinous Tumors and Their Utility in Differentiating Primary Ovarian Mucinous Tumors From Metastatic Pancreatic Mucinous Carcinomas in the Ovary , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[77]  J. Jagirdar Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. , 2008, Archives of pathology & laboratory medicine.

[78]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[79]  S. Culine,et al.  Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) , 2003, British Journal of Cancer.

[80]  A. Gown,et al.  CDX2, a Highly Sensitive and Specific Marker of Adenocarcinomas of Intestinal Origin: An Immunohistochemical Survey of 476 Primary and Metastatic Carcinomas , 2003, The American journal of surgical pathology.

[81]  D Nicholson,et al.  Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. , 1990, Cancer research.

[82]  P. Chu,et al.  Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases , 2002, Modern Pathology.

[83]  E. Wit,et al.  Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. , 2002, Cancer research.

[84]  C. MacKenzie,et al.  ES1, a new lung carcinoma antibody— an immunohistochemical study , 2006, Histopathology.

[85]  N. Pavlidis,et al.  Cancer of Unknown Primary Origin. , 1997, The oncologist.

[86]  W. McCluggage,et al.  Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms , 2000, Journal of clinical pathology.

[87]  N. Ordóñez The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma , 2003, The American journal of surgical pathology.

[88]  S. Yohe,et al.  Application of immunohistochemistry to soft tissue neoplasms. , 2008, Archives of pathology & laboratory medicine.

[89]  L. Weiss,et al.  Usefulness of immunohistochemistry in delineating renal spindle cell tumours. A retrospective study of 31 cases , 2004, Histopathology.

[90]  J. Pimiento,et al.  Cancer of unknown primary origin: a decade of experience in a community-based hospital. , 2007, American journal of surgery.

[91]  Dietel,et al.  Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B , 2000, Histopathology.

[92]  J. Quesenberry,et al.  Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. , 1992, American journal of clinical pathology.

[93]  G. Kang,et al.  Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. , 2007, Archives of pathology & laboratory medicine.

[94]  K. Judson,et al.  Distinction of Primary and Metastatic Mucinous Tumors Involving the Ovary: Analysis of Size and Laterality Data by Primary Site With Reevaluation of an Algorithm for Tumor Classification , 2008, The American journal of surgical pathology.

[95]  T. Tot,et al.  Adenocarcinomas metastatic to the liver , 1999, Cancer.

[96]  B. Addis,et al.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies , 2002, Journal of clinical pathology.

[97]  C. Muir Cancer of unknown primary site , 1995, Cancer.

[98]  T. Tot The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal tract , 2000 .

[99]  J. Chan,et al.  Subcellular Localization of Immunohistochemical Signals , 2004, International journal of surgical pathology.

[100]  A. Hartmann,et al.  Cancer of unknown primary: clinicopathologic correlations , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[101]  M. Wick,et al.  Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. , 2000, Seminars in diagnostic pathology.

[102]  M Dietel,et al.  Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. , 2001, American journal of clinical pathology.

[103]  R. Soslow,et al.  Application of immunohistochemistry to gynecologic pathology. , 2009, Archives of pathology & laboratory medicine.

[104]  J. Hainsworth,et al.  Diagnostic and therapeutic management of cancer of an unknown primary. , 2003, European journal of cancer.

[105]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[106]  C. Moskaluk,et al.  Cdx2 Protein Expression in Normal and Malignant Human Tissues: An Immunohistochemical Survey Using Tissue Microarrays , 2003, Modern Pathology.

[107]  P. V. van Diest,et al.  Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. , 1999, Journal of clinical pathology.

[108]  J. Cameron,et al.  Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. , 2004, Human pathology.

[109]  R. Moll,et al.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. , 1992, The American journal of pathology.

[110]  P. Würl,et al.  Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[111]  T. Tot Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. , 2002, European journal of cancer.

[112]  R. Odze,et al.  Immunohistochemistry Can Help Distinguish Metastatic Pancreatic Adenocarcinomas From Bile Duct Adenomas and Hamartomas of the Liver , 2005, The American journal of surgical pathology.

[113]  R. Dhir,et al.  Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma , 2007, Diagnostic pathology.

[114]  Y. Ishikawa,et al.  Pulmonary Adenocarcinomas With Enteric Differentiation: Histologic and Immunohistochemical Characteristics Compared With Metastatic Colorectal Cancers and Usual Pulmonary Adenocarcinomas , 2005, The American journal of surgical pathology.

[115]  C. Pan,et al.  Differential Immunoprofiles of Hepatocellular Carcinoma, Renal Cell Carcinoma, and Adrenocortical Carcinoma: A Systemic Immunohistochemical Survey Using Tissue Array Technique , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[116]  D. Mintzer,et al.  Cancer of unknown primary: changing approaches. A multidisciplinary case presentation from the Joan Karnell cancer center of pennsylvania hospital. , 2004, The oncologist.

[117]  M. Wick,et al.  Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. , 1989, Human pathology.

[118]  K. Oien,et al.  Effusion cytology of hepatocellular carcinoma with in situ hybridisation for human albumin. , 1997, Journal of clinical pathology.

[119]  J. Reis-Filho,et al.  Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray , 2003, Virchows Archiv.

[120]  M. Kinney,et al.  Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. , 2008, Archives of pathology & laboratory medicine.

[121]  Wei-ping Liu,et al.  Comparison of Immunohistochemical Markers in the Differential Diagnosis of Adrenocortical Tumors: Immunohistochemical Analysis of Adrenocortical Tumors , 2007, Applied immunohistochemistry & molecular morphology : AIMM.